William Blair Rates Moderna (MRNA) Market Perform

By TradeTexts Research Desk Oct 27, 2026, 11:24 AM EDT

Key Points

William Blair lowered its rating on Moderna, Inc. to Market Perform on October 27, 2026.
As of October 27, 2026, Moderna shares recently traded at $191.10, down about 0.5% from the previous close of $192.15.
The average price target for Moderna among analysts is $138.37, indicating that the stock is trading above this mean target by about 38.1%.

Get Moderna text alerts

We text you when insiders, Congress, analysts or big funds move on $MRNA.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Moderna, Inc. alert may contain errors. Disclosures

On October 27, 2026, William Blair downgraded its rating on Moderna, Inc. (MRNA) to Market Perform. This change reflects the firm's latest assessment of the stock's performance potential. The action was reported in their research note on the same day.

MRNA Moderna, Inc.

$198.85 +544.36% year to date

Daily close · Oct 26, 2026

Analyst rating track record

William Blair vs. the S&P 500

YTD return -15.16% hypothetical

All-time return -15.16% S&P 500 +0.02%

vs. S&P 500 -15.18% behind the index

Hypothetical returns from William Blair's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Moderna, Inc.

Several other institutions have also recently adjusted their positions in Moderna. Elser Financial Planning added 1,335 shares, bringing its total to 1,335 shares worth about $257,081. Meanwhile, Banque Pictet & Cie reduced its holdings by 548,143 shares, resulting in a total of 2,151,259 shares valued at approximately $414.3 million. Cohen Klingenstein opened a new position with 2,100 shares worth about $404,397. SBI Securities increased its stake by 7,267 shares, totaling 23,692 shares worth about $4.6 million. BAILLIE GIFFORD & CO decreased its position by 1,778,708 shares, ending with 18,206,778 shares valued at around $3.5 billion.

Moderna, Inc. Stock Down 4.5%

As of October 27, 2026, Moderna shares were trading at $191.10, which is about 0.5% below the previous close of $192.15. The stock is currently above its 50-day moving average by about 9.9% and well above its 200-day average by approximately 130.3%. However, it is about 24.9% below its 52-week high of $254.48.

Recent Earnings

Moderna reported trailing twelve-month revenue of $2.23 billion, reflecting a year-over-year growth of 2.1%. The company has faced challenges, with a net margin of -141.4% and a return on equity of -39.0%. Its next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Several insiders have sold shares recently. Chief Financial Officer James M Mock sold 34,836 shares on September 10, 2026, at an average price of $134.49, totaling about $4.68 million. President Stephen Hoge sold 80,575 shares on September 15, 2026, valued at around $11.69 million. He also sold 39,145 shares on October 15, 2026, for about $8.64 million.

Analysts Set New Price Targets

Piper Sandler had just raised its target to $230 on October 26, 2026, maintaining an Overweight rating. The consensus among analysts is a Hold rating with a mean price target of $138.37.

About Moderna, Inc.

Moderna, Inc. is a biotechnology company based in Cambridge, MA, that specializes in messenger RNA medicines. Its products and research are focused on developing vaccines and therapeutics for various diseases, making it a key player in the healthcare sector.

Bottom Line

Investors should watch for Moderna's upcoming earnings report on November 6, 2026, as well as any further analyst updates following William Blair's recent downgrade. The stock's performance relative to its peers and market conditions will also be important to monitor in the coming weeks.